Axovant (AXGT) Prices 14.03M Share Common Offering at $3.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Axovant Gene Therapies Announces Pricing of $65 Million Public Offering
February 19, 2020 10:10 PM ESTNEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share. In addition, and in lieu of common shares, Axovant is offering to certain investors pre-funded warrants to purchase 3,301,998 common shares at a purchase price of $3.74999 per pre-funded warrant, which represents the per share public offering price for the common shares, minus the $0.00001 per share exercise price of each such pre-funded warrant. The... More



